U.S. drug developer Capricor places Duchenne drug trial on hold
The trial, named "HOPE-2", was testing the company's lead experimental drug CAP-1002, according to California-based Capricor's website.
New Delhi: Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy(DMD), a muscle-wasting disorder, citing a safety review.
The review follows a severe allergic reaction during infusion of the drug, the company said in a filing. The patient responded well to medical treatment and is currently asymptomatic.
The company has notified the U.S. Food and Drug Administration and is working with the agency on a mitigation plan, it said.
The trial, named "HOPE-2", was testing the company's lead experimental drug CAP-1002, according to California-based Capricor's website.
DMD is a rare, genetic disorder that hampers muscle movement, mainly in men, affecting one in every 3,500 to 5,000 males. More than 90 per cent of patients become wheelchair-bound by age 15.
Also Read: Affimed puts on hold cancer drug trial after patient death
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd